A major investor wants Bristol-Myers to “expand its [immunotherapy] portfolio as much as possible,” potentially through a merger with another drugmaker, an unnamed source told Bloomberg.
Analysts identified Pfizer, Novartis and Gilead Sciences as potential candidates to takeover the drugmaker.
Despite talk of a deal, Bristol-Myers is urging investors to wait for new trial results and scientific data on a myriad of combination therapies — some of which combine Opdivo with other drugs, according to the report.
A breakthrough combination therapy would expand the market for Opdivo, which represents nearly 20 percent of Bristol-Myers’ $19.4 billion in annual revenue, reports Bloomberg.
More articles on supply chain:
7 drugmakers in the headlines
4 ways hospitals can lower inpatient drug costs
6 must-reads for supply chain leaders this week
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.